"Designing Growth Strategies is in our DNA"

Intravenous Immunoglobulins Market Size, Share and Global Trend By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Geography Forecast till 2025

Region : Global | Latest Update: Jul, 2019 | Published Date: Jun, 2019 | Report ID: FBI100593| Status : Published

 

KEY INDUSTRY INSIGHTS

The Global Intravenous Immunoglobulins Market Was Valued at US$ 9,787.6 Mn in 2017 And is Projected to Reach US$ 15,789.1 Mn by The End of 2025, Exhibiting A CAGR of 6.2%.

Immunoglobulins are the glycoprotein molecules manufactured by the plasma or the white blood cells. Immunoglobulins form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction. Intravenous immunoglobulins are the immunoglobulins that are administered through the intravenous route. Intravenous immunoglobulins are the most common route of administration because most of the patients receiving immunoglobulins are in the hospital and clinical settings. This, coupled with the proven efficiency of the immunoglobulins as an effective treatment option for a number of immune diseases and the lack of training for homecare settings is also positively driving the market growth. Some of the other factors which are also contributing to the growth of the intravenous immunoglobulins market is its dominance in the both the developed and the developing markets. The ongoing R&D by major market players for the introduction of new and advanced intravenous immunoglobulins is expected to drive the growth of the intravenous immunoglobulins market in developed as well as emerging countries, during the forecast period 2018-2025. 

Get comprehensive study about this report by, request a sample copy

Primary Immunodeficiency (PI) To Account For The Highest Market Share By 2025 

The adoption of intravenous immunoglobulin therapy as the first line of treatment for the primary immunodeficiency and other rare immunological and neurological diseases, is one of the most prominent leading to factors that are responsible for the growth of the global intravenous immunoglobulins market in 2017. Primary Immunodeficiency (PI) segment is estimated to have the largest market share among the indication segment. The Primary Immunodeficiency (PI) segment accounted for a market share of 28.6% in 2017 and is expected to increase during the forecast period. Increasing focus towards the diagnosis of primary immunodeficiency and the subsequent treatment based on the individual case and training of the patient, in most cases the patient is not adept in self administration, is also driving the primary immunodeficiency segment. The chronic inflammatory demyelinating polyneuropathy (CIDP) segment is estimated to grow at a slower CAGR during the forecast period. This is attributed to the comparatively lower prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP). Currently, there is an existing dominance of the primary immunodeficiency (PI) as the indication for which intravenous immunoglobulin is the most prescribed for and this is expected to contribute to the growth of the market at higher CAGR during the forecast period. 

To get details on market share, speak to our analyst

An Increase In The Number Of Immunodeficiences Diagnoses Due To Greater Awareness, Along With Increasing Adoption of Immunoglobulins Expected to Result in the Highest CAGR in the Asia Pacific 

The intravenous immunoglobulins market in North America was valued at US$ 5,587.4 Mn in 2017 and is anticipated to account for a dominant share in the global intravenous immunoglobulins market during the forecast period. The primary driving factor for the significant and strong growth of the intravenous immunoglobulins market is the fact that it is the first line of treatment for a number of critical immune disorders. With the increase in contributing factors of such as the increasing number of patients and the efficiency of the intravenous immunoglobulins as treatment option, is expected to give rise to a significant demand for immunoglobulins. In developed countries, the adoption of advanced intravenous immunoglobulins is growing alongside the increasing number of indications that are approved. India and China in the Asia Pacific region are experiencing growth in the immunoglobulins due to increased diagnosis of primary immunodefiencies in the population. In terms of the dominance of indication, primary immunodeficiency is the most dominating indication in these developing regions. However, in countries like Japan, there is increased adoption and expenditure towards advanced immunoglobulins and Japan holds significant revenue shares in these advanced immunoglobulins. 

North America Intravenous Immunoglobulins Market, 2017

To get geographical overview of this market, request a sample copy

Grifols, S.A., is anticipated to be the leading player in the intravenous immunoglobulins market 

Grifols, S.A., emerged as the leading player with the highest market share in 2017, as the company has a number of product offerings in the intravenous immunoglobulins market across a wide range of indications and it is the commonly used route of administration, and these product offerings dominate a substantial portion of market share. The company accounts for the highest revenue shares in the immunoglobulins from regions such as North America and Europe. In addition, other market players are also getting product approvals such as Shire (Takeda Pharmaceutical Company Limited). The company received regulatory approvals for the immunoglobulin product offering of CUVITRU. Other players operating in the global intravenous immunoglobulins market are CSL Behring, Grifols, S.A., Kedrion S.p.A, Octapharma, Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB SA and Shanghai RAAS Blood Products Co., Ltd. 

Report Overview  

Immunoglobulins, also referred to as antibodies, are the glycoprotein molecules manufactured by the plasma or the white blood cells. Immunoglobulins form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction. In certain individuals, immunoglobulins have to be administered for the treatment and management of diseases such as primary immunodeficiency (PI). The report on global intravenous immunoglobulins market focuses on market size in terms of revenue (US$ Mn), of intravenous immunoglobulins, for the period 2014-2025. 

The report offers information pertaining to various dynamics of the market including drivers, restraints, opportunities for market players in the global intravenous immunoglobulins market, and trends. The report analyzes and evaluates the current market size, growth rate, and forecast of the global intravenous immunoglobulins market, with regards to indication (primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN) and others). On the basis of form, the market can be segmented into liquid and lyophilized. On the basis of end user, the market can be segmented into hospitals, clinics and homecare. 

The report also offers key insights related to an overview of the intravenous immunoglobulins market (2017) - for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, pipeline analysis, overview of regulatory scenario by key regions, key industry developments, number (estimated) of primary immunodeficiency (PI) patients by key countries and reimbursement scenario. 

Key segments within the market

To get information on various segments, share your queries with us

SEGMENTATION

 SEGMENTATION 

 DETAILS 

By Indication

·         Primary Immunodeficiency

·         Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

·         Guillain-Barré Syndrome (GBS)

·         Immune Thrombocytopenic Purpura (ITP)

·         Multifocal Motor Neuropathy (MMN)

·         Others

By Form

·         Liquid

·         Lyophilized

By End User

·         Hospitals

·         Clinics

·         Homecare

By Geography

·         North America (the U.S., and Canada)

·         Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)

·         Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)

·         Latin America (Brazil, Mexico, and Rest of Latin America

·         Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)

 Key companies covered in the report

  • Shire (Takeda Pharmaceutical Company Limited)
  • CSL Behring
  • Grifols, S.A.
  • Kedrion S.p.A
  • Octapharma
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • LFB SA
  • Shanghai RAAS Blood Products Co., Ltd.
  • Other players

Key Industry Developments

  • In May 2019, the FDA approved the prior approval supplement (PAS) for ADMA Biologics, Inc.’s product offering of BIVIGAM and subsequently ADMA announced that it will begin the commercial sales of the product
  • In April 2019, a novel intravenous immunoglobulin by ADMA Biologics, Inc. to be utilised for the treatment of primary immunodeficiency called Asceniv (Immune Globulin Intravenous, Human – slra 10%, Liquid), received the FDA approval

Intravenous Immunoglobulins Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2017
  • 2014-2016
  • 145

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X